A first-in-class, agnostic, host-directed precision medicine treatment for acute respiratory distress syndrome

Xfibra, Inc. received a $3.42 million Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on September 15, 2025, with a completion date of September 14, 2027. The award supports the development of a first-in-class, agnostic, host-directed precision medicine treatment for acute respiratory distress syndrome (ARDS). Research and development activities will be conducted at the company's facility in Del Mar, California.

As a self-certified small disadvantaged business and woman-owned small business entity, Xfibra will leverage its specialized expertise in fibrosis treatment development to advance novel therapeutic approaches for ARDS through this two-year research initiative. The award aligns with the DHA's broader portfolio of biomedical research focused on transforming healthcare for military service members and the American public through innovative medical solutions addressing critical health challenges.